References
- Morton LM, Onel K, Curtis RE, Hungate EA, Armstrong GT. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book 2014:e57-67.
- Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2328-38. https://doi.org/10.1200/JCO.2008.21.1425
- Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100:1368-79. https://doi.org/10.1093/jnci/djn310
- Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008;26:392-8. https://doi.org/10.1200/JCO.2007.13.3033
- Prochazka M, Hall P, Gagliardi G, et al. Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. J Clin Oncol 2005;23:7467-74. https://doi.org/10.1200/JCO.2005.01.7335
- Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-92. https://doi.org/10.1093/jnci/94.3.182
- Cooke R, Jones ME, Cunningham D, et al. Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. Br J Cancer 2013;108:2399-406. https://doi.org/10.1038/bjc.2013.219
- De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009;27:4239-46. https://doi.org/10.1200/JCO.2008.19.9174
- Varszegi D, Duga B, Melegh BI, et al. Hodgkin disease therapy induced second malignancy susceptibility 6q21 functional variants in roma and hungarian population samples. Pathol Oncol Res 2014;20:529-33. https://doi.org/10.1007/s12253-013-9724-z
- Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009;113:5575-82.
- Mullenders L, Atkinson M, Paretzke H, Sabatier L, Bouffler S. Assessing cancer risks of low-dose radiation. Nat Rev Cancer 2009;9:596-604. https://doi.org/10.1038/nrc2677
- Taylor AM, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol 2005;58:1009-15. https://doi.org/10.1136/jcp.2005.026062
- Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007;168:1-64. https://doi.org/10.1667/RR0763.1
- Berrington de Gonzalez A, Gilbert E, Curtis R, et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys 2013;86:224-33. https://doi.org/10.1016/j.ijrobp.2012.09.001
- Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007;25:1489-97. https://doi.org/10.1200/JCO.2006.09.0936
- Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-65. https://doi.org/10.1093/jnci/dji278
- Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2010;184:16-20. https://doi.org/10.1016/j.cbi.2009.10.009
- Kayser S, Dohner K, Krauter J, et al. The impact of therapyrelated acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137-45. https://doi.org/10.1182/blood-2010-08-301713
- Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29:4096-104. https://doi.org/10.1200/JCO.2011.34.8268
- Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013;14:72-80. https://doi.org/10.1016/S1470-2045(12)70525-9
- Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014;15:333-42. https://doi.org/10.1016/S1470-2045(13)70609-0
- Zhao J, Xu Z, Liu D, Lu Q. Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell Int 2012;12:38. https://doi.org/10.1186/1475-2867-12-38
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84. https://doi.org/10.1016/S0140-6736(11)60993-8
- Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006;65:1-7. https://doi.org/10.1016/j.ijrobp.2006.01.027
- 1990 Recommendations of the International Commission on Radiological Protection. Ann ICRP 1991;21:1-201. https://doi.org/10.1016/0146-6453(91)90009-6
- Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102:1083-95. https://doi.org/10.1093/jnci/djq238
- Armstrong GT, Sklar CA, Hudson MM, Robison LL. Long-term health status among survivors of childhood cancer: does sex matter? J Clin Oncol 2007;25:4477-89. https://doi.org/10.1200/JCO.2007.11.2003
- Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009;27:2356-62. https://doi.org/10.1200/JCO.2008.21.1920
- Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002;2:124-32. https://doi.org/10.1038/nrc722
- Krueger SA, Joiner MC, Weinfeld M, Piasentin E, Marples B. Role of apoptosis in low-dose hyper-radiosensitivity. Radiat Res 2007;167:260-7. https://doi.org/10.1667/RR0776.1
- Harrison RM, Wilkinson M, Rawlings DJ, Moore M. Doses to critical organs following radiotherapy and concomitant imaging of the larynx and breast. Br J Radiol 2007;80:989-95. https://doi.org/10.1259/bjr/32814323
- Newhauser WD, Durante M. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer 2011;11:438-48. https://doi.org/10.1038/nrc3069
- Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 2013;87:46-52. https://doi.org/10.1016/j.ijrobp.2013.04.030
- Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol 2016;17:287-98. https://doi.org/10.1016/S1470-2045(15)00167-9
- Eaton BR, Esiashvili N, Kim S, et al. Clinical outcomes among children with standard-risk medulloblastoma treated with proton and photon radiation therapy: a comparison of disease control and overall survival. Int J Radiat Oncol Biol Phys 2016;94:133-8. https://doi.org/10.1016/j.ijrobp.2015.09.014
- Sethi RV, Shih HA, Yeap BY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 2014;120:126-33. https://doi.org/10.1002/cncr.28387
- Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 2009;91:4-15. https://doi.org/10.1016/j.radonc.2008.12.016
- Grantzau T, Mellemkjær L, Overgaard J. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: a national population based study under the Danish Breast Cancer Cooperative Group (DBCG). Radiother Oncol 2013;106:42-9. https://doi.org/10.1016/j.radonc.2013.01.002
- Berrington de Gonzalez A, Curtis RE, Gilbert E, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010;102:220-6. https://doi.org/10.1038/sj.bjc.6605435
- Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol 2015;114:56-65.
- Hamilton SN, Tyldesley S, Li D, Olson R, McBride M. Second malignancies after adjuvant radiation therapy for early stage breast cancer: is there increased risk with addition of regional radiation to local radiation? Int J Radiat Oncol Biol Phys 2015;91:977-85. https://doi.org/10.1016/j.ijrobp.2014.12.051
- Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398-406. https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V
- Berrington de Gonzalez A, Wong J, Kleinerman R, Kim C, Morton L, Bekelman JE. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors. Int J Radiat Oncol Biol Phys 2015;91:295-302.
- Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634-43. https://doi.org/10.1093/jnci/djm201
- Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e631-8. https://doi.org/10.1016/j.ijrobp.2011.04.013
- O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010;28:1232-9. https://doi.org/10.1200/JCO.2009.24.8062
- Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108-15. https://doi.org/10.1002/cncr.21971
- Foss Abrahamsen A, Andersen A, Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 2002;13:1786-91. https://doi.org/10.1093/annonc/mdf289
- Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 2011;305:2311-9. https://doi.org/10.1001/jama.2011.747
- Henderson TO, Oeffinger KC, Whitton J, et al. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med 2012;156:757-66, W-260. https://doi.org/10.7326/0003-4819-156-11-201206050-00002
- Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol 1998;16:3761-7. https://doi.org/10.1200/JCO.1998.16.12.3761
- Ralleigh G, Given-Wilson R. Breast cancer risk and possible screening strategies for young women following supradiaphragmatic irradiation for Hodgkin's disease. Clin Radiol 2004;59:647-50. https://doi.org/10.1016/j.crad.2004.04.003
- Mulder RL, Kremer LC, Hudson MM, et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2013;14:e621-9. https://doi.org/10.1016/S1470-2045(13)70303-6
- Howell SJ, Searle C, Goode V, et al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer 2009;101:582-8. https://doi.org/10.1038/sj.bjc.6605215
- Page V, Gardner A, Karzmark CJ. Physical and dosimetric aspects of the radiotherapy of malignant lymphomas. I. The mantle technique. Radiology 1970;96:609-18. https://doi.org/10.1148/96.3.609
- Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-52. https://doi.org/10.1056/NEJMoa1000067
- Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79:270-7. https://doi.org/10.1016/j.radonc.2006.05.015
- Hoskin PJ, Diez P, Williams M, Lucraft H, Bayne M; Participants of the Lymphoma Radiotherapy Group. Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) 2013;25:49-58. https://doi.org/10.1016/j.clon.2012.07.011
- Swerdlow AJ, Cooke R, Bates A, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol 2012;30:2745-52. https://doi.org/10.1200/JCO.2011.38.8835
- Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84. https://doi.org/10.1056/NEJM199901143400201
- Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289-301. https://doi.org/10.1038/nrclinonc.2013.41
- Inskip PD, Robison LL, Stovall M, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009;27:3901-7. https://doi.org/10.1200/JCO.2008.20.7738
- Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 2010;174:741-52. https://doi.org/10.1667/RR2240.1
- Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-75. https://doi.org/10.1001/jama.290.4.465
- Rubino C, Shamsaldin A, Le MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 2005;89:277-88. https://doi.org/10.1007/s10549-004-2472-8
- Boice JD Jr, Engholm G, Kleinerman RA, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988;116:3-55. https://doi.org/10.2307/3577477
- Gilbert ES, Stovall M, Gospodarowicz M, et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003;159:161-73. https://doi.org/10.1667/0033-7587(2003)159[0161:LCATFH]2.0.CO;2
- Taylor AJ, Little MP, Winter DL, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 2010;28:5287-93. https://doi.org/10.1200/JCO.2009.27.0090
- Morton LM, Gilbert ES, Hall P, et al. Risk of treatment-related esophageal cancer among breast cancer survivors. Ann Oncol 2012;23:3081-91. https://doi.org/10.1093/annonc/mds144
Cited by
- Reduction of Delayed Homologous Recombination by Induction of Radioadaptive Response in RaDR-GFP Mice (Yonezawa Effect): An Old Player With a New Role vol.17, pp.1, 2019, https://doi.org/10.1177/1559325819833840
- A Case of Histiocytic Sarcoma Arising from Mycosis Fungoides vol.2019, pp.None, 2018, https://doi.org/10.1155/2019/7834728
- Effect of dose constraint on the thyroid gland during locoregional intensity‐modulated radiotherapy in breast cancer patients vol.20, pp.7, 2019, https://doi.org/10.1002/acm2.12668
- Heart‐sparing radiotherapy with three‐dimensional printing technology after mastectomy for patients with left breast cancer vol.25, pp.4, 2018, https://doi.org/10.1111/tbj.13304
- Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma vol.4, pp.13, 2019, https://doi.org/10.1172/jci.insight.128698
- Zweitmalignomrisiko nach Behandlung von lokal begrenzten Prostatakarzinomen mit Kohlenstoffionen möglicherweise niedriger als nach Photonenbestrahlung vol.195, pp.11, 2018, https://doi.org/10.1007/s00066-019-01510-0
- The mutational footprints of cancer therapies vol.51, pp.12, 2018, https://doi.org/10.1038/s41588-019-0525-5
- Angiosarcomaafteradjuvantradiotherapy in high-risksquamouscell carcinoma of the vulva: a case report vol.18, pp.4, 2019, https://doi.org/10.5114/pm.2019.93114
- Graphene Quantum Dot-Based Electrochemical Immunosensors for Biomedical Applications vol.13, pp.1, 2018, https://doi.org/10.3390/ma13010096
- Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies vol.8, pp.None, 2018, https://doi.org/10.3389/fchem.2020.00571
- Cancer Risk of Low Dose Ionizing Radiation vol.8, pp.None, 2018, https://doi.org/10.3389/fphy.2020.00234
- Clinical and epidemiological observations on individual radiation sensitivity and susceptibility vol.96, pp.3, 2020, https://doi.org/10.1080/09553002.2019.1665209
- Nanoparticles as Tools to Target Redox Homeostasis in Cancer Cells vol.9, pp.3, 2018, https://doi.org/10.3390/antiox9030211
- Modern radiotherapy for pediatric rhabdomyosarcoma vol.71, pp.1, 2018, https://doi.org/10.5937/mp71-24163
- Role of Rad51 and DNA repair in cancer: A molecular perspective vol.208, pp.None, 2020, https://doi.org/10.1016/j.pharmthera.2020.107492
- Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment vol.26, pp.None, 2018, https://doi.org/10.2174/1381612826666201002145454
- Radiation-Induced Brachial Plexopathy in Breast Cancer and the Role of Surgical Treatment vol.9, pp.2, 2018, https://doi.org/10.1055/s-0040-1712272
- Examination of a dose evaluation method for floor-mounted kV X-ray image-guided radiation therapy systems vol.13, pp.3, 2020, https://doi.org/10.1007/s12194-020-00570-7
- Updated Understanding of Cancer as a Metabolic and Telomere-Driven Disease, and Proposal for Complex Personalized Treatment, a Hypothesis vol.21, pp.18, 2020, https://doi.org/10.3390/ijms21186521
- Current trends in the management of subependymal giant cell astrocytomas in tuberous sclerosis vol.36, pp.10, 2020, https://doi.org/10.1007/s00381-020-04889-9
- The diagnosis and management of primary and iatrogenic soft tissue sarcomas of the sella vol.23, pp.5, 2018, https://doi.org/10.1007/s11102-020-01062-y
- Radiation therapy and secondary malignancy in Li‐Fraumeni syndrome: A hereditary cancer registry study vol.9, pp.21, 2020, https://doi.org/10.1002/cam4.3427
- BCL‐XL exerts a protective role against anemia caused by radiation‐induced kidney damage vol.39, pp.24, 2018, https://doi.org/10.15252/embj.2020105561
- Rare presentation of radiation-induced sarcoma detected on F-18 FDG positron emission tomography/computed tomography in a treated case of giant cell tumor vol.36, pp.4, 2018, https://doi.org/10.4103/ijnm.ijnm_61_21
- Impact of Advanced Radiotherapy on Second Primary Cancer Risk in Prostate Cancer Survivors: A Nationwide Cohort Study vol.11, pp.None, 2021, https://doi.org/10.3389/fonc.2021.771956
- Telomere Length Dynamics and Chromosomal Instability for Predicting Individual Radiosensitivity and Risk via Machine Learning vol.11, pp.3, 2021, https://doi.org/10.3390/jpm11030188
- Laryngeal Langerhans Cell Histiocytosis: A Case Report and Literature Review vol.130, pp.4, 2018, https://doi.org/10.1177/0003489420954883
- Management of tenosynovial giant cell tumour of the foot and ankle vol.b103, pp.4, 2021, https://doi.org/10.1302/0301-620x.103b4.bjj-2020-1582.r1
- Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings vol.41, pp.3, 2021, https://doi.org/10.1148/rg.2021200171
- Risk of second cancer among young prostate cancer survivors vol.39, pp.2, 2018, https://doi.org/10.3857/roj.2020.00857
- Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study vol.106, pp.7, 2018, https://doi.org/10.1210/clinem/dgab192
- CANCER-INDUCED DIAGNOSTIC AND THERAPEUTIC INTERVENTIONS vol.20, pp.4, 2018, https://doi.org/10.21294/1814-4861-2021-20-4-146-151
- Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial vol.39, pp.26, 2018, https://doi.org/10.1200/jco.21.00596
- Spleen angiosarcoma: a world review vol.15, pp.10, 2021, https://doi.org/10.1080/17474124.2021.1945920
- Unintended dose to the lower axilla in adjuvant radiotherapy for breast cancer: Differences between tangential beam and VMAT vol.164, pp.None, 2021, https://doi.org/10.1016/j.radonc.2021.10.005
- 3D Breast Tumor Models for Radiobiology Applications vol.13, pp.22, 2018, https://doi.org/10.3390/cancers13225714
- Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy vol.125, pp.10, 2018, https://doi.org/10.1038/s41416-021-01549-w
- May Different Treatment Volumes and Technical Approaches Have an Impact on Second Malignancies Risk? vol.39, pp.33, 2021, https://doi.org/10.1200/jco.21.01790
- Dosimetry and outcomes in patients receiving radiotherapy for synchronous bilateral breast cancers vol.52, pp.4, 2018, https://doi.org/10.1016/j.jmir.2021.08.013
- Mathematical model for the thermal enhancement of radiation response: thermodynamic approach vol.11, pp.1, 2018, https://doi.org/10.1038/s41598-021-84620-z
- Analysis of lncRNA-miRNA-mRNA expression pattern in heart tissue after total body radiation in a mouse model vol.19, pp.1, 2018, https://doi.org/10.1186/s12967-021-02998-w
- Implications of targeted next-generation sequencing for bladder cancer: report of four cases vol.19, pp.1, 2018, https://doi.org/10.1186/s43141-021-00182-7
- Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment vol.14, pp.1, 2018, https://doi.org/10.3390/cancers14010126